OBJECTIVES Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous beta-thalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of deferasirox (DFX) side effects in patients with thalassemia major or intermedia. METHODS A retrospecti...

BACKGROUND Available iron chelation regimes in thalassaemia may achieve different changes in cardiac and hepatic iron as assessed by MR. The aim of this study was to assess the efficacy of four available iron chelator regimes in 232 thalassaemia major patients by assessing the rate of change in repeated measurements of cardiac and hepatic MR. RESULTS For the heart, deferiprone and the combina...

Background: Iron overload is frequently found in transfused patients with chronic anemia and congenital hemochromatosis. toxicity adversely affects organs, including the heart, liver, endocrine glands. chelation helps transfusion-related iron improve organ dysfunction prolong survival.Current Concepts: classified into primary secondary causes. Acquired causes of include ineffective erythropoies...

abstract background iron overload is a major problem in patients with major thalassemia. an effective and safe iron chelator protocol with high compliance rate plays an important role in treatment of these patients. this study was done to assess the efficacy and safety of the sequential deferoxamine and deferasirox protocol in major thalassemia patients in khuzestan province, iran. material and...

utilized iron chelator produced a dramatic effect on survival of patients with thalassemia. However, DFO has poor oral bioavailability and a short half life, necessitating 12 hours of subcutaneous infusion, rendering therapy extremely cumbersome [1]. Deferiprone (DFP), an orally effective iron chelator, reduces total body iron load and is also effective in removing cardiac iron [1-3]. However, ...

The US04 trial was a multicenter, open-label, single arm trial of deferasirox monotherapy (30-40 mg/kg/day) for 18 months. Cardiac iron response was bimodal with improvements observed in patients with mild to moderate initial somatic iron stores; relationship of cardiac response to labile plasma iron is now presented. Labile plasma iron was measured at baseline, six months, and 12 months. In pa...

.a simple spectrofluorimetric method is described for the determination of doxorubicin (dxr) based on its quenching effect on the fluorescence intensity of tb 3+ - deferasirox (dfx) complex as a fluorescent probe. the excitation and emission wavelengths were 328 and 545 nm, respectively. the effects of ph, time, order of addition of reagents, concentrations of tb 3+ and dfx and the buffer volum...